Record NNP B-NP O
date NN I-NP O
: : O O
2061-10-03 CD O B-DATE
BMH NNP B-NP B-HOSPITAL
Cancer NNP I-NP O
Center NNP I-NP O
Hematology NNP B-NP O
Note NN I-NP O
Fellow NNP B-NP O
: : O O
James NNP B-NP B-DOCTOR
Tyler NNP I-NP I-DOCTOR
Attending VBG B-VP O
: : O O
Cole NNP B-NP B-DOCTOR
Morgan NNP I-NP I-DOCTOR
Date NNP B-NP O
of IN B-PP O
consultation NN B-NP O
: : O O
October NNP B-NP B-DATE
04 CD I-NP I-DATE
, , I-NP I-DATE
2061 CD O I-DATE
Diagnosis NNP B-NP O
: : O O
thrombocytosis NN B-NP O
, , I-NP O
reactive NN I-NP O
vs. CC I-NP O
essential JJ I-NP O
thrombocytosis NN I-NP O
HPI NNP B-NP O
: : O O
27 CD B-NP B-AGE
yo JJ I-NP O
African JJ I-NP O
American JJ I-NP O
male NN I-NP O
with IN B-PP O
recent JJ B-NP O
complicated JJ I-NP O
hospital NN I-NP O
stay NN I-NP O
at IN B-PP O
BMH NNP B-NP B-HOSPITAL
presents NNS I-NP O
to TO B-PP O
hematology NN B-NP O
clinic NN I-NP O
for IN B-PP O
first JJ B-NP O
time NN I-NP O
for IN B-PP O
follow VB B-VP O
up IN B-PRT O
of IN B-PP O
his PRP$ B-NP O
thrombocytosis NN I-NP O
. . O O
This DT B-NP O
27 CD I-NP B-AGE
yo NNP I-NP O
male JJ I-NP O
with IN B-PP O
history NN B-NP O
of IN B-PP O
type NN B-NP O
I PRP B-NP O
DM MD O O
who WP B-NP O
does VBZ B-VP O
not RB I-VP O
get VB I-VP O
regular JJ B-NP O
medical JJ I-NP O
care NN I-NP O
in IN B-PP O
late JJ B-NP O
August NNP I-NP B-DATE
was VBD B-VP O
visiting VBG I-VP O
family NN B-NP O
in IN B-PP O
Maryland NNP B-NP B-STATE
and CC O O
had VBD B-VP O
sudden JJ B-NP O
witnessed VBN I-NP O
seizure NN I-NP O
activity NN I-NP O
. . O O
At IN B-PP O
the DT B-NP O
time NN I-NP O
, , O O
blood NN B-NP O
sugar NN I-NP O
was VBD B-VP O
>500 CD B-NP O
. . O O
Upon IN B-PP O
initial JJ B-NP O
arrival NN I-NP O
to TO B-PP O
the DT B-NP O
ER NNP I-NP O
in IN B-PP O
Maryland NNP B-NP B-STATE
, , O O
he PRP B-NP O
has VBZ B-VP O
BP NNP B-NP O
248/146 CD I-NP O
; : O O
plt NN B-NP O
count NN I-NP O
was VBD B-VP O
in IN B-PP O
800's JJ B-NP O
. . O O
The DT B-NP O
patient NN I-NP O
was VBD B-VP O
intubated VBN I-VP O
, , O O
treated VBN B-VP O
for IN B-PP O
HTN NNP B-NP O
with IN B-PP O
labetolol NN B-NP O
and CC O O
placed VBD B-VP O
on IN B-PP O
IV NNP B-NP O
insulin NN I-NP O
and CC I-NP O
dilantin NN I-NP O
and CC O O
transferred VBD B-VP O
to TO B-PP O
BMH NNP B-NP B-HOSPITAL
for IN B-PP O
further JJ B-NP O
care NN I-NP O
. . O O
At IN B-PP O
BMH NNP B-NP B-HOSPITAL
, , O O
MRI NNP B-NP O
showed VBD B-VP O
several JJ B-NP O
small JJ I-NP O
areas NNS I-NP O
of IN B-PP O
infarct NN B-NP O
read VBN B-VP O
as IN B-PP O
concerning VBG B-VP O
for IN B-PP O
embolic JJ B-NP O
CVA NNP I-NP O
- : O O
echo NN B-NP O
was VBD B-VP O
done VBN I-VP O
showing VBG B-VP O
no DT B-NP O
vegetations NNS I-NP O
, , O O
no DT B-NP O
PFO NNP I-NP O
, , O O
NL NNP B-NP O
EF NNP I-NP O
with IN B-PP O
LVH NNP B-NP O
; : O O
TEE NNP B-NP O
without IN B-PP O
vegetations NNS B-NP O
as RB B-ADVP O
well RB I-ADVP O
. . O O
LP '' O O
was VBD B-VP O
done VBN I-VP O
and CC I-VP O
sent VBN I-VP O
for IN B-PP O
HSV NNP B-NP O
which WDT B-NP O
was VBD B-VP O
negative JJ B-ADJP O
. . O O
He PRP B-NP O
underent VBD B-VP O
a DT B-NP O
renal JJ I-NP O
workup NN I-NP O
which WDT B-NP O
showed VBD B-VP O
nephrotic JJ B-NP O
range NN I-NP O
proteinuria NN I-NP O
; : O O
labs NNS B-NP O
also RB B-ADVP O
showed VBD B-VP O
rhabdoymyolysis NN B-NP O
. . O O
Renal NNP B-NP O
doppler NN I-NP O
US PRP B-NP O
showed VBD B-VP O
no DT B-NP O
sign NN I-NP O
of IN B-PP O
RAS. NNP B-NP O
He PRP B-NP O
was VBD B-VP O
continued VBN I-VP O
on IN B-PP O
abx NN B-NP O
for IN B-PP O
his PRP$ B-NP O
aspiration NN I-NP O
PNA NNP B-NP O
. . O O
Other JJ B-NP O
parts NNS I-NP O
of IN B-PP O
the DT B-NP O
secondary JJ I-NP O
htn NN I-NP O
workup NN I-NP O
were VBD B-VP O
done VBN I-VP O
including VBG I-VP O
evaluation NN B-NP O
for IN B-PP O
hyper NN B-NP O
aldo RB B-ADVP O
, , O O
pheo NN B-NP O
. . O O
The DT B-NP O
vent NN I-NP O
was VBD B-VP O
weaned VBN I-VP O
and CC O O
he PRP B-NP O
was VBD B-VP O
extubated VBN I-VP O
on IN B-PP O
the DT B-NP O
4th JJ I-NP B-DATE
. . O O
HTN NNP B-NP O
was VBD B-VP O
controlled VBN I-VP O
with IN B-PP O
labetolol NN B-NP O
drip NN I-NP O
with IN B-PP O
additional JJ B-NP O
oral JJ I-NP O
agents NNS I-NP O
being VBG B-VP O
added VBN I-VP O
. . O O
He PRP B-NP O
continued VBD B-VP O
to TO I-VP O
have VB I-VP O
intermittent JJ B-NP O
fevers NNS I-NP O
and CC O O
was VBD B-VP O
on IN B-PP O
broad JJ B-NP O
antibiotics NNS I-NP O
which WDT B-NP O
were VBD B-VP O
originally RB I-VP O
weaned VBN I-VP O
off RP B-PRT O
. . O O
Hematologically RB B-ADVP O
, , O O
the DT B-NP O
hct NN I-NP O
and CC I-NP O
wbc NN I-NP O
fell VBD B-VP O
as IN B-SBAR O
he PRP B-NP O
was VBD B-VP O
hydrated JJ B-ADJP O
. . O O
Plt '' O O
count NN B-NP O
stayed VBD B-VP O
stable JJ B-ADJP O
in IN B-PP O
the DT B-NP O
600 CD I-NP O
's POS I-NP O
for IN B-PP O
several JJ B-NP O
days NNS I-NP O
before IN B-PP O
increasing VBG B-VP O
on IN B-PP O
the DT B-NP O
3rd NN I-NP B-DATE
gradually RB B-ADVP O
up RB I-ADVP O
to TO B-PP O
the DT B-NP O
1000 CD I-NP O
's POS B-NP O
. . I-NP O
Retics NNP I-NP O
were VBD B-VP O
depressed VBN I-VP O
at IN B-PP O
presentation NN B-NP O
and CC I-NP O
iron NN I-NP O
studies NNS I-NP O
were VBD B-VP O
c/w JJ B-NP O
ACD NNP I-NP O
and CC O O
he PRP B-NP O
was VBD B-VP O
started VBN I-VP O
on IN B-PP O
epogen NN B-NP O
. . O O
Initially RB O O
it PRP B-NP O
was VBD B-VP O
felt VBN I-VP O
that IN B-PP O
his PRP$ B-NP O
thrombocytosis NN I-NP O
was VBD B-VP O
most RBS B-ADVP O
certainly RB I-ADVP O
reactive VBP B-VP O
; : O O
CRP NNP B-NP O
was VBD B-VP O
>150 CD B-NP O
with IN B-PP O
ESR NNP B-NP O
>100 CD I-NP O
. . O O
He PRP B-NP O
left VBD B-VP O
the DT B-NP O
ICU NNP I-NP O
and CC B-PP O
at IN B-PP O
this DT B-NP O
point NN I-NP O
his PRP$ B-NP O
WBC NNP I-NP O
trended VBD B-VP O
down RB B-ADVP O
and CC O O
he PRP B-NP O
was VBD B-VP O
afebrile JJ B-ADJP O
and CC O O
more RBR B-ADJP O
clinically RB I-ADJP O
stable JJ I-ADJP O
. . O O
But CC O O
his PRP$ B-NP O
platelets NNS I-NP O
kept VBD B-VP O
climbing VBG I-VP O
to TO B-PP O
nearly RB B-NP O
1.5 CD I-NP O
million CD I-NP O
. . O O
A DT B-NP O
bone NN I-NP O
marrow NN I-NP O
biopsy NN I-NP O
was VBD B-VP O
done VBN I-VP O
showing VBG B-VP O
no DT B-NP O
cytogenetics NNS I-NP O
to TO B-VP O
suggest VB I-VP O
CML NNP B-NP O
and CC O O
there EX B-NP O
were VBD B-VP O
elevated VBN B-NP O
megakaryocytes NNS I-NP O
read VBD B-VP O
as IN B-PP O
concerning VBG B-VP O
for IN B-PP O
a DT B-NP O
myeloproliferative JJ I-NP O
process NN I-NP O
. . O O
As IN O O
well RB B-ADVP O
, , O O
he PRP B-NP O
suffered VBD B-VP O
a DT B-NP O
DVT NNP I-NP O
in IN B-PP O
his PRP$ B-NP O
subclavian/IJ NN I-NP O
on IN B-PP O
the DT B-NP O
same JJ I-NP O
side NN I-NP O
as IN B-PP O
a DT B-NP O
central JJ I-NP O
venous JJ I-NP O
catheter NN I-NP O
. . O O
Given VBN B-VP O
his PRP$ B-NP O
thrombocytosis NN I-NP O
and CC O O
elevated VBD B-VP O
plt NN B-NP O
count NN I-NP O
, , O O
he PRP B-NP O
was VBD B-VP O
platelet VBN I-VP O
pheresed VBN I-VP O
twice RB B-ADVP O
in IN B-PP O
the DT B-NP O
hospital NN I-NP O
. . B-NP O
As IN I-NP O
well RB B-ADVP O
, , O O
hydrea NN B-NP O
was VBD B-VP O
started VBN I-VP O
at IN B-PP O
this DT B-NP O
time NN I-NP O
, , O O
initially RB B-ADVP O
at IN B-PP O
500mg CD B-NP O
bid NN I-NP O
and CC O O
then RB O O
escalated VBD B-VP O
to TO B-PP O
1000mg CD B-NP O
bid NN I-NP O
when WRB B-ADVP O
his PRP$ B-NP O
counts NNS I-NP O
were VBD B-VP O
up RB B-ADVP O
to TO B-PP O
800-900 CD B-NP O
despite IN B-PP O
the DT B-NP O
medication NN I-NP O
. . O O
As IN O O
well RB B-ADVP O
, , O O
he PRP B-NP O
suffered VBD B-VP O
a DT B-NP O
small JJ I-NP O
GI NNP I-NP O
bleed VBD B-VP O
due JJ B-ADJP O
to TO B-PP O
an DT B-NP O
ulcer NN I-NP O
. . O O
For IN B-PP O
this DT B-NP O
reason NN I-NP O
he PRP B-NP O
was VBD B-VP O
not RB O O
anticoagulated JJ B-ADJP O
but CC I-ADJP O
placed VBN I-ADJP O
upon IN B-PP O
daily JJ B-NP O
ASA NNP I-NP O
. . O O
He PRP B-NP O
was VBD B-VP O
discharged VBN I-VP O
from IN B-PP O
the DT B-NP O
hospital NN I-NP O
two CD B-NP O
weeks NNS I-NP O
ago RB B-ADVP O
and CC O O
has VBZ B-VP O
done VBN I-VP O
fairly RB B-ADVP O
well RB I-ADVP O
since IN B-PP O
then RB B-NP O
. . O O
His PRP$ B-NP O
energy NN I-NP O
has VBZ B-VP O
been VBN I-VP O
good JJ B-ADJP O
. . O O
He PRP B-NP O
denies VBZ B-VP O
any DT B-NP O
fevers/chills/sweats NNS I-NP O
. . O O
No DT B-NP O
bleeding/bruising NN I-NP O
. . B-VP O
No DT B-NP O
further RBR I-NP O
swelling VBG B-VP O
in IN B-PP O
his PRP$ B-NP O
arms/legs NNS I-NP O
. . O O
He PRP B-NP O
does VBZ B-VP O
have VB I-VP O
some DT B-NP O
occasionally RB I-NP O
blurryness NN I-NP O
in IN B-PP O
eyes NNS B-NP O
immediately RB B-ADVP O
after IN B-PP O
taking VBG B-VP O
his PRP$ B-NP O
anti-hypertensives NNS I-NP O
but CC O O
no DT B-NP O
numnbess/weakness/dizziness NN I-NP O
. . O O
Problems/PMH: NNS B-NP O
DM NNP B-NP O
type NN I-NP O
1 CD I-NP O
since IN B-PP O
age NN B-NP O
12 CD I-NP B-AGE
no DT B-NP O
recollection NN I-NP O
of IN B-PP O
any DT B-NP O
abnormal JJ I-NP O
blood NN I-NP O
counts VBZ B-VP O
prior JJ B-ADJP O
to TO B-PP O
this DT B-NP O
admit VB I-NP O
New NNP B-NP O
diagnoses NNS I-NP O
on IN B-PP O
this DT B-NP O
admit VB I-NP O
renal JJ B-NP O
insufficiency NN I-NP O
nephrotic JJ B-NP O
proteinuria NN I-NP O
malignant JJ B-NP O
hypertension NN I-NP O
thrombocytosis NN B-NP O
GI NNP B-NP O
bleed VBP B-VP O
- : O O
upper JJ B-ADJP O
with IN B-PP O
ulcer NN B-NP O
visualized VBN B-VP O
on IN B-PP O
EGD NNP B-NP O
small JJ B-NP O
embolic JJ I-NP O
appearing VBG I-NP O
CVA NNP I-NP O
's POS O O
Medications NNS B-NP O
: : O O
Diovan NNP B-NP O
lisinopril NN B-NP O
Hydrea NNP B-NP O
1000 CD I-NP O
bid NN I-NP O
ASA NNP B-NP O
81 CD I-NP O
qod NN I-NP O
lopressor NN B-NP O
procardia NN B-NP O
clonidine NN B-NP O
nexium . O O
insulin NN B-NP O
: : O O
am VBP B-VP O
25 CD B-NP O
regular/34 CD I-NP O
NPH NNP I-NP O
, , O O
pm VBP B-VP O
20 CD B-NP O
regular/28 CD I-NP O
NPH . O O
Allergies NNP B-NP O
: : O O
nkda . O O
Social NNP B-NP O
History NNP I-NP O
: : O O
lives NNS B-NP O
in IN B-PP O
waycross NN B-NP B-CITY
; : O O
single JJ O O
works NNS B-NP O
in IN B-PP O
Geologist NNP B-NP B-PROFESSION
no DT B-NP O
tob NN I-NP O
reports NNS B-NP O
social JJ B-NP O
etoh NN I-NP O
Family NNP B-NP O
History NN I-NP O
: : O O
htn NN B-NP O
Physical JJ B-NP O
Examination NNP I-NP O
: : O O
Vital JJ B-NP O
Signs NNS I-NP O
BP NNP B-NP O
101/63 CD I-NP O
, , O O
P NNP B-NP O
64 CD I-NP O
, , O O
RR NNP B-NP O
16 CD I-NP O
, , O O
Temp NNP B-NP O
98.1 CD I-NP O
F NNP I-NP O
, , I-NP O
Wt NNP I-NP O
202 CD I-NP O
lb NN I-NP O
gen NN B-NP O
: : O O
well-appearing JJ B-NP O
male NN I-NP O
, , O O
alert JJ B-NP O
, , I-NP O
conversant JJ I-NP O
, , I-NP O
nad CC O O
heent NN B-NP O
: : O O
supple NN B-NP O
, , O O
non-icteric JJ B-ADVP O
, , O O
no DT B-NP O
cervical/supraclav NN I-NP O
adenopathy NN I-NP O
chest NN B-NP O
: : O O
clear JJ O O
cv NN B-NP O
: : O O
reg NN B-NP O
abd NN B-NP O
; : O O
benign JJ B-ADVP O
with IN B-PP O
no DT B-NP O
hsm NN I-NP O
ext NN B-NP O
: : O O
trace NN B-NP O
LE JJ I-NP O
edema NN I-NP O
, , O O
no DT B-NP O
upper JJ I-NP O
edema NN I-NP O
skin NN B-NP O
: : O O
scattered VBN B-NP O
ulcerations NNS I-NP O
on IN B-PP O
his PRP$ B-NP O
arms NNS I-NP O
with IN B-PP O
granulation NN B-NP O
tissue NN I-NP O
, , O O
scarred VBD B-VP O
vesicular JJ B-NP O
changes NNS I-NP O
on IN B-PP O
his PRP$ B-NP O
neck NN I-NP O
Data NNP B-NP O
: : O O
10/03/2061 CD B-NP B-DATE
WBC NNP I-NP O
4.1 CD I-NP O
( -LRB- I-NP O
L) NNP I-NP O
, , O O
RBC NNP B-NP O
3.95 CD I-NP O
( -LRB- I-NP O
L) NNP I-NP O
, , O O
HGB NNP B-NP O
12.0 CD I-NP O
( -LRB- I-NP O
L) NNP I-NP O
, , O O
HCT NNP B-NP O
35.5 CD I-NP O
( -LRB- I-NP O
L) NNP I-NP O
, , O O
MCV NNP B-NP O
90 CD I-NP O
, , O O
MCH NNP B-NP O
30.4 CD I-NP O
, , O O
MCHC NNP B-NP O
33.8 CD I-NP O
, , O O
PLT NNP B-NP O
601 CD I-NP O
( -LRB- O O
H) NN O O
10/03/2061 CD B-NP B-DATE
RDW NNP I-NP O
17.2 CD I-NP O
( -LRB- O O
H) NN O O
10/03/2061 CD B-NP B-DATE
DIFFR NNP I-NP O
RECEIVED NNP I-NP O
, , O O
METHOD NNP B-NP O
, , O O
%NEUT NNP B-NP O
57 CD I-NP O
, , O O
%LYMPH NNP B-NP O
36 CD I-NP O
, , O O
%MONO NN B-NP O
3 CD I-NP O
( -LRB- I-NP O
L) NN I-NP O
, , O O
%EOS NNP B-NP O
3 CD I-NP O
, , O O
%BASO NNP B-NP O
1 CD I-NP O
10/03/2061 CD B-NP B-DATE
ANEUT NNP I-NP O
2.35 CD I-NP O
, , O O
ALYMP NNP B-NP O
1.48 CD I-NP O
, , O O
AMONS NNP B-NP O
0.10 CD I-NP O
( -LRB- I-NP O
L) NNP I-NP O
, , O O
AEOSN NNP B-NP O
0.10 CD I-NP O
, , O O
ABASOP NNP B-NP O
0.02 CD I-NP O
10/03/2061 CD B-NP B-DATE
RETIC NN I-NP O
1.0 CD O O
Assessment NNP B-NP O
and CC I-NP O
Plan NNP I-NP O
: : O O
Interesting VBG B-NP O
case NN I-NP O
of IN B-PP O
a DT B-NP O
27 CD I-NP B-AGE
yo NNP I-NP O
male NN I-NP O
with IN B-PP O
insulin NN B-NP O
dependent JJ I-NP O
diabetes NNS I-NP O
and CC O O
apparent JJ B-NP O
untreated JJ I-NP O
HTN NN I-NP O
who WP B-NP O
presented VBD B-VP O
with IN B-PP O
seizure NN B-NP O
in IN B-PP O
setting NN B-NP O
of IN B-PP O
hypertensive JJ B-NP O
emergency NN I-NP O
and CC O O
is VBZ B-VP O
found VBN I-VP O
with IN B-PP O
nephrotic JJ B-NP O
syndrome NN I-NP O
, , O O
renal JJ B-NP O
insufficiency NN I-NP O
, , O O
several JJ B-NP O
small JJ I-NP O
embolic-appearing NN I-NP O
strokes NNS I-NP O
and CC O O
has VBZ B-VP O
developed VBN I-VP O
marked VBN I-VP O
thrombocytopenia IN B-PP O
to TO B-NP O
1.5 CD I-NP O
million CD I-NP O
and CC O O
had VBD B-VP O
subsequent JJ B-NP O
provoked VBN I-NP O
DVT. NNP I-NP O
He PRP B-NP O
was VBD B-VP O
treated VBN I-VP O
for IN B-PP O
concern NN B-NP O
of IN B-PP O
essential JJ B-NP O
thrombocytosis NN I-NP O
in IN B-PP O
hospital NN B-NP O
with IN B-PP O
platelet NN B-NP O
pheresis NN I-NP O
then RB B-ADVP O
hydrea NN B-VP O
. . B-NP O
Today NN I-NP O
, , O O
he PRP B-NP O
presents VBZ B-VP O
looking VBG I-VP O
well RB B-ADVP O
and CC I-ADVP O
still RB I-ADVP O
has VBZ B-VP O
a DT B-NP O
thrombocytosis NN I-NP O
despite IN B-PP O
the DT B-NP O
hydrea NN I-NP O
. . O O
It PRP B-NP O
is VBZ B-VP O
still RB B-ADVP O
not RB O O
possible JJ B-ADJP O
to TO B-VP O
tell VB I-VP O
for IN B-PP O
sure JJ B-NP O
if IN B-SBAR O
this DT B-NP O
is VBZ B-VP O
still RB B-ADVP O
a DT B-NP O
reactive NN I-NP O
thrombocytosis IN B-PP O
vs JJ B-NP O
Essential NNP I-NP O
thrombocytosis NN I-NP O
. . O O
At IN B-PP O
the DT B-NP O
moment NN I-NP O
, , O O
we PRP B-NP O
will MD B-VP O
continue VB I-VP O
to TO I-VP O
treat VB I-VP O
this DT B-NP O
as IN B-PP O
ET NNP B-NP O
and CC O O
will MD B-VP O
continue VB I-VP O
hydrea NN B-NP O
at IN B-PP O
the DT B-NP O
current JJ I-NP O
dose NN I-NP O
and CC O O
ask VB B-VP O
him PRP B-NP O
to TO B-VP O
take VB I-VP O
aspirin NN B-NP O
81 CD B-NP O
mg NN I-NP O
qd VBD B-VP O
. . O O
If IN B-SBAR O
this DT B-NP O
is VBZ B-VP O
a DT B-NP O
reactive JJ I-NP O
process NN I-NP O
, , O O
time NN B-NP O
should MD B-VP O
be VB I-VP O
a DT B-NP O
good JJ I-NP O
diagnostic JJ I-NP O
test NN I-NP O
at IN B-PP O
this DT B-NP O
should MD B-VP O
improve VB I-VP O
after IN B-SBAR O
he PRP B-NP O
is VBZ B-VP O
further RB B-ADVP O
from IN B-PP O
his PRP$ B-NP O
complicated JJ I-NP O
hospital/icu NN I-NP O
stay NN I-NP O
. . O O
At IN B-PP O
his PRP$ B-NP O
next JJ I-NP O
visit NN I-NP O
with IN B-PP O
us PRP B-NP O
next JJ B-NP O
month NN I-NP O
we PRP B-NP O
will MD B-VP O
recheck VB I-VP O
his PRP$ B-NP O
C-reactive JJ I-NP O
protein NN I-NP O
, , O O
ESR NNP B-NP O
, , O O
iron NN B-NP O
studies/ferritin NN I-NP O
for IN B-PP O
some DT B-NP O
idea NN I-NP O
of IN B-PP O
whether IN O O
his PRP$ B-NP O
body NN I-NP O
could MD B-VP O
still RB I-VP O
be VB I-VP O
mounting VBG I-VP O
an DT B-NP O
inflammatory JJ I-NP O
response NN I-NP O
to TO B-VP O
drive VB I-VP O
a DT B-NP O
reactive JJ I-NP O
thrombocytosis NN I-NP O
. . O O
If IN B-PP O
his PRP$ B-NP O
plt NN I-NP O
count NN I-NP O
comes VBZ B-VP O
down RP B-PRT O
, , O O
we PRP B-NP O
will MD B-VP O
be VB I-VP O
able JJ B-ADJP O
to TO B-VP O
start VB I-VP O
tapering VBG I-VP O
his PRP$ B-NP O
hydrea NN I-NP O
at IN B-PP O
that DT B-NP O
time NN I-NP O
. . O O
Of IN B-PP O
note NN B-NP O
, , O O
in IN B-PP O
the DT B-NP O
near JJ I-NP O
future NN I-NP O
, , O O
we PRP B-NP O
may MD B-VP O
be VB I-VP O
able JJ B-ADJP O
to TO B-VP O
help VB I-VP O
determine VB I-VP O
between IN B-PP O
reactive JJ B-NP O
and CC I-NP O
essential JJ I-NP O
process NN I-NP O
with IN B-PP O
measurement NN B-NP O
of IN B-PP O
the DT B-NP O
JAK2 JJ I-NP O
kinase NN I-NP O
level NN I-NP O
. . O O
In IN B-PP O
the DT B-NP O
meantime NN I-NP O
, , O O
he PRP B-NP O
will MD B-VP O
be VB I-VP O
meeting VBG I-VP O
with IN B-PP O
his PRP$ B-NP O
new JJ I-NP O
PCP NNP I-NP O
and CC I-NP O
renal JJ I-NP O
physician NN I-NP O
next JJ B-NP O
week NN I-NP O
. . O O
James NNP B-NP B-DOCTOR
B. NNP I-NP I-DOCTOR
Tyler NNP I-NP I-DOCTOR
, , O O
M.D. NNP B-NP O
